The 100 organoids are derived from the tumors of patients with colorectal, oesophageal and pancreatic cancer. Available to researchers worldwide, they will enable studies into cancer development and ...

Australian researchers have grown tumours in the lab to accurately predict what drugs will work for people with bowel cancer – before they begin treatment.

Researchers have created model tumors using the tissues of patients with advanced bowel cancer and used them to predict how the disease will respond to specific drug therapies – before treatment ...

Signet’s organoid models, derived from real-world cancer genomics data, can closely mimic human biology in 3D tissues to identify novel targets and evaluate drug efficacy with greater clinical ...

A patient-derived tumor organoid platform could identify the most effective chemotherapy strategies for appendix and colon cancer patients.

A patient-specific tumor organoid platform could someday take the guessing game out of immunotherapy treatments.

Scientists at Johns Hopkins Medicine and colleagues say they have created a lab-grown organoid model that is derived from human tissue and designed to advance understanding about how early stages ...

Pancreatic ductal adenocarcinoma (PDAC), that arises from pancreatic epithelial cells, is the most common form of pancreatic cancer, with a very high mortality rate.

Challenges and prospects Co-culturing tumor organoids with immune cells brings 3D organoid models closer to their in vivo state, offering valuable models for precision cancer therapy.

The idea is that the organoid can serve as a laboratory model for the person with cancer, and that drugs that kill cells in the organoid are more likely to effectively treat their tumour.